Research Paper Volume 14, Issue 19 pp 7941—7958

Figure 7. Effect of ERAP2 knockdown on tumorigenesis and gemcitabine sensitivity in pancreatic cancer cell lines. (A) Cell viability assay in two pancreatic cancer cell lines treated with ERAP2 knockdown, gemcitabine alone or gemcitabine with ERAP2 knockdown. (B) Cell proliferation assay in two pancreatic cancer cell lines treated with ERAP2 knockdown, gemcitabine alone or gemcitabine with ERAP2 knockdown. (C) Wound healing assay in two pancreatic cancer cell lines treated with ERAP2 knockdown, gemcitabine alone or gemcitabine with ERAP2 knockdown. (D) Transwell invasion assay in two pancreatic cancer cell lines treated with ERAP2 knockdown, gemcitabine alone or gemcitabine with ERAP2 knockdown. Data were shown as the mean ± SEM of three independent experiments (*p < 0.05, **p < 0.01 and ***p < 0.001).